Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Non-Current Liabilities (2016 - 2024)

BioCorRx (BICX) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $12.7 million as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 23.85% to $12.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Dec 2024, up 23.85% year-over-year, with the annual reading at $12.7 million for FY2024, 23.85% up from the prior year.
  • Total Non-Current Liabilities hit $12.7 million in Q4 2024 for BioCorRx, up from $12.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.7 million in Q4 2024 to a low of $9.0 million in Q4 2022.
  • Historically, Total Non-Current Liabilities has averaged $11.2 million across 3 years, with a median of $11.3 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: increased 14.71% in 2023 and later increased 23.85% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $9.0 million in 2022, then rose by 14.71% to $10.3 million in 2023, then rose by 23.85% to $12.7 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for BICX at $12.7 million in Q4 2024, $12.6 million in Q3 2024, and $11.5 million in Q2 2024.